首页> 外文OA文献 >EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia

【2h】

EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia

机译：EBV阳性淋巴抑制性疾病，具有髓质，脾脏和肝脏浸润后的甲磺酸治疗后慢性骨髓性白血病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
T Leguay; C Foucaud; M Parrens; O Fitoussi; K Bouabdallah; M A Belaud-Rotureau; R Tabrizi; G Marit; A Pigneux; N Milpied;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia [J] . T Leguay, C Foucaud, M Parrens, Leukemia . 2007,第10期

机译：甲磺酸伊马替尼治疗慢性粒细胞白血病后，EBV阳性淋巴增生性疾病伴髓样，脾和肝浸润
2. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response [J] . YhimH.-Y., LeeN.-R., SongE.-K., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2012,第6期

机译：接受甲磺酸伊马替尼一线治疗并获得完全分子应答的慢性骨髓性白血病患者中的甲磺酸伊马替尼停药
3. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. [J] . Pawarode A, Sait SN, Nganga A, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2007,第11期

机译：在没有新的细胞遗传学异常的情况下，甲磺酸伊马替尼治疗慢性粒细胞白血病期间发生急性粒细胞白血病。
4. Proteomic Analysis of the Cytoskeleton Regulation in Chronic Myelogenous Leukemia Cells JURL-MK1: Effect of Imatinib Mesylate Treatment [C] . Petr Halada, Katerina Peslova, Dana Grebenova, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：慢性髓性白血病细胞Jull-MK1中细胞骨架调控的蛋白质组学分析：伊马替尼甲磺酸盐处理的影响
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia [O] . Junko Yamaguchi, Takahiro Fujino, Reiko Isa, 2019

机译：甲磺酸伊马替尼治疗慢性粒细胞白血病期间与爱泼斯坦-巴尔病毒相关的淋巴增生性疾病
7. Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia [O] . Junko Yamaguchi, Takahiro Fujino, Reiko Isa, 2019

机译：慢性髓性白血病伊马替尼甲磺酸盐治疗期间Epstein-BARR病毒相关的淋巴抑制性疾病
8. Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 3, Imatinib for Chronic Myeloid Leukemia (CML) [R] . Abernethy, A. P., McCrory, D. C. 2005

机译：报告口服癌疗法对医疗保险受益人与目前报道疗法的相对疗效：第3部分，伊马替尼治疗慢性粒细胞白血病（CmL）

EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅